Literature DB >> 12665695

Complement components and their autoantibodies.

P Norsworthy1, K A Davies.   

Abstract

The purpose of the immune system is to defend the host from constantly changing microbial pathogens. Autoimmune diseases develop as a consequence of the production of antibodies and/or cells that react with self-antigens, and may recruit other effector mechanisms that result in tissue damage. Thus, in this context, autoimmunity represents an immune response to self-antigens that is sufficient to cause disease. This article is specifically devoted to autoantibodies directed against complement components.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12665695     DOI： 10.1385/MB:23:3:259

Source DB:  PubMed          Journal:  Mol Biotechnol        ISSN： 1073-6085            Impact factor:   2.860


  42 in total

1.  Antibody to a cryptic, solid phase C1Q antigen in membranoproliferative nephritis.

Authors:  C F Strife; A E Leahy; C D West
Journal:  Kidney Int       Date:  1989-03       Impact factor: 10.612

2.  Antibodies to the collagen-like region of C1q in sera of patients with autoimmune rheumatic diseases.

Authors:  M H Wener; S Uwatoko; M Mannik
Journal:  Arthritis Rheum       Date:  1989-05

3.  Mesangiocapillary nephritis, partial lipodystrophy, and hypocomplementaemia.

Authors:  D K Peters; J A Charlesworth; J G Sissons; D G Williams; J M Boulton-Jones; D J Evans; O Kourilsky; L Morel-Maroger
Journal:  Lancet       Date:  1973-09-08       Impact factor: 79.321

4.  Serum C'3 lytic system in patients with glomerulonephritis.

Authors:  R E Spitzer; E H Vallota; J Forristal; E Sudora; A Stitzel; N C Davis; C D West
Journal:  Science       Date:  1969-04-25       Impact factor: 47.728

5.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

6.  Nephritic factor of the classical pathway of complement: immunoglobulin G autoantibody directed against the classical pathway C3 convetase enzyme.

Authors:  L Halbwachs; M Leveillé; P Lesavre; S Wattel; J Leibowitch
Journal:  J Clin Invest       Date:  1980-06       Impact factor: 14.808

7.  Two types of C3 nephritic factor: properdin-dependent C3NeF and properdin-independent C3NeF.

Authors:  Y Tanuma; H Ohi; M Hatano
Journal:  Clin Immunol Immunopathol       Date:  1990-08

8.  Epitope mapping of C1 inhibitor autoantibodies from patients with acquired C1 inhibitor deficiency.

Authors:  S He; S Tsang; J North; N Chohan; R B Sim; K Whaley
Journal:  J Immunol       Date:  1996-03-01       Impact factor: 5.422

9.  C1q solid-phase radioimmunoassay: evidence for detection of antibody directed against the collagen-like region of C1q in sera from patients with systemic lupus erythematosus.

Authors:  S Uwatoko; S Aotsuka; M Okawa; Y Egusa; R Yokohari; C Aizawa; K Suzuki
Journal:  Clin Exp Immunol       Date:  1987-07       Impact factor: 4.330

10.  Significance of C3 nephritic factor (C3NeF) in non-hypocomplementaemic serum with membranoproliferative glomerulonephritis (MPGN).

Authors:  H Ohi; S Watanabe; T Fujita; T Yasugi
Journal:  Clin Exp Immunol       Date:  1992-09       Impact factor: 4.330
View more
  2 in total

1.  Sensitive and specific assays for C3 nephritic factors clarify mechanisms underlying complement dysregulation.

Authors:  Danielle Paixão-Cavalcante; Margarita López-Trascasa; Lillemor Skattum; Patricia C Giclas; Timothy H Goodship; Santiago Rodríguez de Córdoba; Lennart Truedsson; B Paul Morgan; Claire L Harris
Journal:  Kidney Int       Date:  2012-08-01       Impact factor: 10.612

2.  Anti-C1q autoantibodies, novel tests, and clinical consequences.

Authors:  Michael Mahler; Rosanne A van Schaarenburg; Leendert A Trouw
Journal:  Front Immunol       Date:  2013-05-14       Impact factor: 7.561
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.